Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17700298 | 0.88 | POLB (0.44) | POLBSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL27915128 | 0.86 | CA12 (0.38) | POLBSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL6898820 | 0.82 | ALDH1A1 (0.45) | SMN1; SMN2LMNA | |
| SCHEMBL4619371 | 0.82 | SMN1; SMN2 (0.54) | POLBSMN1; SMN2HSD11B1KMT2A | |
| SCHEMBL9326006 | 0.77 | CA12 (0.41) | POLBCA12CA1CA2CA7 | |
| SCHEMBL3923273 | 0.75 | CNR2 (0.51) | POLBCA12CA1CA2CA7 | |
| SCHEMBL17978734 | 0.75 | MEN1 (0.51) | POLBSMN1; SMN2KMT2ALMNAKIF11 | |
| SCHEMBL17420520 | 0.74 | ACSS2 (0.47) | POLBSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL9326889 | 0.73 | CNR2 (0.41) | POLBCA12CA1CA2CA7 | |
| SCHEMBL21447568 | 0.72 | HSD11B1 (0.52) | POLBSMN1; SMN2HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703504-B2 | HAVING SUBSTANTIAL ORIENTATIONAL RIGIDITY OF AROMATIC RINGS WITH RESPECT TO CENTRAL INDANE MOIETY AND ELECTRON DONATING FUNCTIONALITY WHICH PROMINENTLY ACTIVATES AND ACCELERATES ELECTROPHILIC AROMATIC SUBSTITUTION OF PARENT RINGS | Slemon, Clarke (CA) | 2004-03-09 | — | — | US | disclosed |
| US-20030232932-A1 | Conformationally constrained compounds as dendrimer cores | SLEMON, CLARKE (CA) | 2003-12-18 | — | — | US | disclosed |
| WO-2003064501-A1 | CONFORMATIONALLY RESTRICTED COMPOUNDS AS DENDRIMER CORES | SLEMON CLARKE (CA) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232932-A1 | Conformationally constrained compounds as dendrimer cores | PCNA, PICALM, CROCC | POLB 152/4885SMN1; SMN2 4487/4885CA12 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.